Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

7.650
-0.070-0.91%
Volume:5.47M
Turnover:41.23M
Market Cap:7.37B
PE:-23.32
High:7.790
Open:7.380
Low:7.220
Close:7.720
Loading ...

BUZZ-China's Ascletis hits 6-year peak on good results for weight loss drug

Reuters
·
12 Mar

Ascletis' Anti-Obesity Drug Found Safe in Australia Phase 1B Trial; Shares Rise 6%

MT Newswires Live
·
12 Mar

BRIEF-Ascletis Pharma Announces Positive Phase Ib Results And FDA Clearance

Reuters
·
12 Mar

Ascletis Pharma Inc - Announces Positive Phase Ib Results and FDA Clearance

THOMSON REUTERS
·
12 Mar

Ascletis Pharma Inc - No Clinically Significant Changes in Liver Enzymes Observed

THOMSON REUTERS
·
19 Feb

Ascletis Announces Positive Interim Results From First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30

THOMSON REUTERS
·
19 Feb

Ascletis Pharma Inc - Cohort 3 Expected to Be Completed by End of March 2025

THOMSON REUTERS
·
19 Feb

Ascletis Pharma Inc - Asc30 Well Tolerated With No Serious Adverse Events in Mad Cohorts 1 and 2

THOMSON REUTERS
·
19 Feb

Ascletis Pharma Sees Positive Results from Obesity Drug Study

MT Newswires Live
·
22 Jan

Ascletis Pharma Inc - Asc30 Shows Dose-Proportional Pk Properties and Long Half-Life up to 60 Hours

THOMSON REUTERS
·
21 Jan

Ascletis Announces Positive Results From U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Provides Program Update

THOMSON REUTERS
·
21 Jan

Ascletis Pharma Inc: Topline Results From U.S. Phase Ib Multiple Ascending Dose Study of Asc30 Oral Tablet, Expected by End of March 2025

THOMSON REUTERS
·
21 Jan

Ascletis Pharma Inc - Asc30 Generally Safe and Well Tolerated in Phase Ia Study

THOMSON REUTERS
·
21 Jan

Bullish Ascletis Pharma Insiders Rewarded As Their Investment Rises To CN¥37.4m

Simply Wall St.
·
17 Jan

Ascletis Pharma Obesity Drug Shows Promising Preclinical Trial Results

MT Newswires Live
·
19 Dec 2024

BRIEF-Ascletis Pharma Inc Updates On ASC47

Reuters
·
18 Dec 2024

Ascletis Pharma Inc - Asc47 in Combination With Semaglutide Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

THOMSON REUTERS
·
18 Dec 2024

The recent 19% gain must have brightened CEO Jinzi Jason Wu's week, Ascletis Pharma Inc.'s (HKG:1672) most bullish insider

Simply Wall St.
·
17 Dec 2024